News

Major clinical trials are looking to answer substantial questions in the treatment of patients with chronic lymphocytic leukemia, according to Matthew Davids, MD, MMSc.

Tebentafusp-tebn has been granted FDA approval to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma based on positive results from a phase 3 study.

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.

Globally, there is no established standard of care treatment for this patient population once patients failed on front-line platinum-based chemotherapy. Lenvatinib plus pembrolizumab is a new option.

A 67-year-old woman presented with a painless lump on her neck. A physical examination showed a palpable, nontender solitary neck mass to the right of the midline.

For the treatment of patients with myelodysplastic syndrome, the FDA has granted an orphan drug designation to eltanexor.

In an interview with Targeted Oncology, Shannon N. Westin, MD, MPH, FACOG, reviewed the recent tweet chat around a high-grade epithelial ovarian cancer case.

The anti-CD47 antibody, AO-176, has been granted an FDA orphan drug designation for relapsed or refractory myeloma treatment and is being assessed in a phase 1/2 study.

The KOMET-001 study may resume after the FDA lifted the partial clinical hold for safety.

LIBRETTO-531 succeeds LIBRETTO-001 to continue the study of selpercatinib in patients with multikinase inhibitor therapy-naive RET-mutant advanced medullary thyroid cancer.

Results from the ongoing phase 3 MOMENTUM clinical trial may be available by the end of Janaury 2022.

In an interview with Targeted Oncology, Ron Bose, MD, MPH, discussed HER2 drug resistance, its impact on treatment, and how new research may help in the future.

With an orphan drug designation in tow, MT-601 will soon be investigated in combination with chemotherapy in phase 1 clinical trial.

Pending results from the ENGOT-en9/LEAP-001 will determine whether the combination of pembrolizumab and lenvatinib prolongs survival more than chemotherapy in patients with endometrial cancer.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

American Oncology network has announced that the organization is partnering with Rapides Cancer Center to provide advanced, comprehensive, and convenient care for patients in Central Louisiana.

A medical oncologist, Shalin R. Shah, DO, is the newest member of the American Oncology Network's executive board.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.

Gedatolisib has earned attention from the FDA after demonstrating encouraging efficacy and safety in a phase 1b clinical trial.

During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.

In an interview with Targeted Oncology, Jennifer Brown, MD, PhD discussed the early analysis of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia and deletion 17p.

Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.

The FDA is reviewing a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy as a first-line treatment option for patients with advanced non-small cell lung cancer.

Retrospective data show that only 24% of patients treated with immune checkpoint inhibitors required immunosuppression while the rest recovered over time.

A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

At the 63rd ASH Annual Meeting and Exposition, studies highlighted the promise of Bruton's tyrosine kinase inhibitors for the treatment of patients with mantle cell lymphoma and what oncologists should do after Bruton's tyrosine kinase inhibition.

The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.